Skip to main content
Advertisement

Main menu

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET

User menu

  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Molecular Pharmacology
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET
  • My alerts
  • Log in
  • My Cart
Molecular Pharmacology

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Visit molpharm on Facebook
  • Follow molpharm on Twitter
  • Follow molpharm on LinkedIn

Table of Contents

November 01, 1989; Volume 36,Issue 5
  • You have access
    Modification of the rat adipocyte A1 adenosine receptor-adenylate cyclase system during chronic exposure to an A1 adenosine receptor agonist: alterations in the quantity of GS alpha and Gi alpha are not associated with changes in their mRNAs.
    J P Longabaugh, J Didsbury, A Spiegel and G L Stiles
    Molecular Pharmacology November 1989, 36 (5) 681-688;
  • You have access
    Rat brain dendrotoxin receptors associated with voltage-gated potassium channels: dendrotoxin binding and receptor solubilization.
    R G Sorensen and M P Blaustein
    Molecular Pharmacology November 1989, 36 (5) 689-698;
  • You have access
    Suppression of constitutive cytochrome P-450 gene expression in livers of rats undergoing an acute phase response to endotoxin.
    E T Morgan
    Molecular Pharmacology November 1989, 36 (5) 699-707;
  • You have access
    Role of microtubule assembly in phenytoin teratogenic action in the sea urchin (Arbacia punctulata) embryo.
    S Estus and J L Blumer
    Molecular Pharmacology November 1989, 36 (5) 708-715;
  • You have access
    Suppression of hepatic levels of an ethanol-inducible P-450DM/j by growth hormone: relationship between the increased level of P-450DM/j and depletion of growth hormone in diabetes.
    Y Yamazoe, N Murayama, M Shimada, S Imaoka, Y Funae and R Kato
    Molecular Pharmacology November 1989, 36 (5) 716-722;
  • You have access
    Cytochrome P450IA1 induction and localization in endothelium of vertebrate (teleost) heart.
    J J Stegeman, M R Miller and D E Hinton
    Molecular Pharmacology November 1989, 36 (5) 723-729;
  • You have access
    Synthetic isoprenoid photoaffinity labeling of P-glycoprotein specific to multidrug-resistant cells.
    S Akiyama, A Yoshimura, H Kikuchi, T Sumizawa, M Kuwano and Y Tahara
    Molecular Pharmacology November 1989, 36 (5) 730-735;
  • You have access
    Relative substrate activities of structurally related pteridine, quinazoline, and pyrimidine analogs for mouse liver folylpolyglutamate synthetase.
    R G Moran, P D Colman and T R Jones
    Molecular Pharmacology November 1989, 36 (5) 736-743;
  • You have access
    Adenosine is required for ethanol-induced heterologous desensitization.
    L E Nagy, I Diamond, K Collier, L Lopez, B Ullman and A S Gordon
    Molecular Pharmacology November 1989, 36 (5) 744-748;
  • You have access
    Regulation of muscarinic receptor subtypes and their responsiveness in rat brain following chronic atropine administration.
    W Lee and B B Wolfe
    Molecular Pharmacology November 1989, 36 (5) 749-757;
  • You have access
    Ifenprodil is a novel type of N-methyl-D-aspartate receptor antagonist: interaction with polyamines.
    I J Reynolds and R J Miller
    Molecular Pharmacology November 1989, 36 (5) 758-765;
  • You have access
    Distance geometry of alpha-substituted 2,2-diphenylpropionate antimuscarinics.
    R K Gordon, E Breuer, F N Padilla, R M Smejkal and P K Chiang
    Molecular Pharmacology November 1989, 36 (5) 766-772;
  • You have access
    Inhibition and stimulation of photoreceptor phosphodiesterases by dipyridamole and M&B 22,948.
    P G Gillespie and J A Beavo
    Molecular Pharmacology November 1989, 36 (5) 773-781;
  • You have access
    Manoalide: structure-activity studies and definition of the pharmacophore for phospholipase A2 inactivation.
    K B Glaser, M S de Carvalho, R S Jacobs, M R Kernan and D J Faulkner
    Molecular Pharmacology November 1989, 36 (5) 782-788;
  • You have access
    Batrachotoxin and alpha-scorpion toxin stabilize the open state of single voltage-gated sodium channels.
    M E O'Leary and B K Krueger
    Molecular Pharmacology November 1989, 36 (5) 789-795;
  • You have access
    Chronic clonazepam administration decreases gamma-aminobutyric acidA receptor function in cultured cortical neurons.
    L G Miller, R B Roy and C L Weill
    Molecular Pharmacology November 1989, 36 (5) 796-802;
  • You have access
    Coupling of the stimulatory GTP-binding protein Gs to rat synaptic membrane adenylate cyclase is enhanced subsequent to chronic antidepressant treatment.
    H Ozawa and M M Rasenick
    Molecular Pharmacology November 1989, 36 (5) 803-808;
  • You have access
    Mechanism of inhibition of prostaglandin H synthase by eugenol and other phenolic peroxidase substrates.
    D Thompson and T Eling
    Molecular Pharmacology November 1989, 36 (5) 809-817;
  • You have access
    Cytotoxicity of gelonin conjugated to targeting molecules: effects of weak amines, monensin, adenovirus, and adenoviral capsid proteins penton, hexon, and fiber.
    V S Goldmacher, W A Blättler, J M Lambert, G McIntyre and J Stewart
    Molecular Pharmacology November 1989, 36 (5) 818-822;
Back to top
PreviousNext

In this issue

Molecular Pharmacology
Vol. 36, Issue 5
1 Nov 1989
  • Table of Contents
  • Table of Contents (PDF)
  • Index by author
  • Back Matter (PDF)
  • Editorial Board (PDF)
  • Front Matter (PDF)
Sign up for alerts
  • Most Cited
  • Most Read
Loading
  • SB-431542 Is a Potent and Specific Inhibitor of Transforming Growth Factor-β Superfamily Type I Activin Receptor-Like Kinase (ALK) Receptors ALK4, ALK5, and ALK7
  • The G-Protein-Coupled Receptors in the Human Genome Form Five Main Families. Phylogenetic Analysis, Paralogon Groups, and Fingerprints
  • Pharmacological Properties of Y-27632, a Specific Inhibitor of Rho-Associated Kinases
  • Pharmacological characterization of five cloned voltage-gated K+ channels, types Kv1.1, 1.2, 1.3, 1.5, and 3.1, stably expressed in mammalian cell lines.
  • The Orphan Human Pregnane X Receptor Mediates the Transcriptional Activation of CYP3A4 by Rifampicin through a Distal Enhancer Module
More...
Advertisement
  • Home
  • Alerts
Facebook   Twitter   LinkedIn   RSS

Navigate

  • Current Issue
  • Fast Forward by date
  • Fast Forward by section
  • Latest Articles
  • Archive
  • Search for Articles
  • Feedback
  • ASPET

More Information

  • About Molecular Pharmacology
  • Editorial Board
  • Instructions to Authors
  • Submit a Manuscript
  • Customized Alerts
  • RSS Feeds
  • Subscriptions
  • Permissions
  • Terms & Conditions of Use

ASPET's Other Journals

  • Drug Metabolism and Disposition
  • Journal of Pharmacology and Experimental Therapeutics
  • Pharmacological Reviews
  • Pharmacology Research & Perspectives
ISSN 1521-0111 (Online)

Copyright © 2023 by the American Society for Pharmacology and Experimental Therapeutics